title: [Adverse effects of intravenous arsenic trioxide and their prevention].
abstract: OBJECTIVE
  To study the main side effects of As(2)O(3) and the way of prevention.
  
  
  METHODS
  The changes of body weight and various systems of body were observed after treatment with As(2)O(3) injection. The arsenic content in blood, urine and hair was detected with atom absorbed-spectrum analysis.
  
  
  RESULTS
  Mild reactions were observed in 57.43% (147/256) of the patients and they could subside after cessation of arsenic treatment or allotherapy. Chronic mild poisoning manifestations including arsenic furuncle, liver dysfunction and peripheral nerve injury were found in 2.73% (7/256) of the patients and they subsided gradually after treatment. Chronic severe poisoning was found in 1.17% of the patients and all of them died of liver failure. As(2)O(3) might cause decrease of peripheral blood WBC in catabatic patients. There was no infection after allopathy without ceasing arsenic medication. The results showed that As(2)O(3) could distribute over and discharge from the plasma without accumulation in blood. The results also demonstrated the main route of excretion for As(2)O(3) is through urine and there is definite accumulation in the hair 50 days after treatment.
  
  
  CONCLUSIONS
  Most of the side effects of As(2)O(3) are mild and recoverable. Allotherapy could be effective to relieve the complications without stopping arsenic medication. A few patients with complicating hepatitis may suffer from chronic poisoning. As(2)O(3) may cause increase of peripheral blood WBC in induced catabatic APL patients. The side effects must be prevented early.
authors.affiliation: Department of Hematology, The 12th People's Hospital of Guangzhou, Guangzhou 510620, China. gzNanwu@sina.com.cn
authors.forename: Nan
authors.initials: N
authors.lastname: Wu
authors.forename: Long-hu
authors.initials: LH
authors.lastname: Hu
authors.forename: Jin
authors.initials: J
authors.lastname: Zhou
authors.forename: Sheng-jin
authors.initials: SJ
authors.lastname: Fan
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Xue-ying
authors.initials: XY
authors.lastname: Han
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010087:Oxides / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide